PeptideCompareARA-290 — EU research guide.
ARA-290 is a non-erythropoietic peptide derived from the helix B surface of erythropoietin (EPO). It activates the innate repair receptor (IRR) to produce tissue-protective and anti-inflammatory effects without stimulating red blood cell production.
What is ARA-290?
ARA-290 (also called cibinetide) is engineered from the helix-B surface of EPO to selectively activate the heterodimeric EPO receptor (EPOR/CD131 — the innate repair receptor) while avoiding the homodimeric EPOR responsible for erythropoiesis. This dissociation makes it attractive for tissue-protective research without haematological side effects.
What does the research show?
In Phase 2 trials for sarcoidosis-associated small-fibre neuropathy, ARA-290 significantly reduced pain scores and improved corneal nerve fibre density. Studies in neuropathic pain, diabetic neuropathy and metabolic syndrome models show anti-inflammatory and nerve repair effects. A small Phase 2 trial in sarcoidosis neuropathy (n=55) is the most advanced human data.
EU legal status
ARA-290 has no EMA or FDA approval. It completed Phase 2 with promising but limited data. Available from EU research vendors for laboratory research only.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
ARA-290 across EU suppliers
COA-verified EU vendors · Updated monthly